Home > Protocol Summaries: Compounds > retigabine Protocol Summaries: retigabine GSKStudy ID Phase Title Status 113284 phase 2 Open-label, multiple dose study to evaluate the parmacokinetics, safety and tolerability of ezogabine/retigabine as adjunctive treatment in subjects aged from 12 years to less than 18 years with partial onset seizures or Lennox-Gastaut syndrome Suspended 113388 phase 3 RTG113388, a Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects with Partial Onset Seizures (>= 12 years old) and Subjects with Lennox-Gastaut Syndrome (>=12 years old) Recruiting 113413 phase 3 A Multicentre, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults with Partial-Onset Seizures (Extension of Study RGB113905) Recruiting 113905 phase 3 An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults with Partial -Onset Seizures Completed 114552 phase 1 An open label, randomised, repeat dose study to assess the pharmacokinetic performance of five ezogabine/retigabine modified release (MR) formulations at steady state compared to the immediate release (IR) formulation. Completed 114855 phase 3 A randomised, double-blind, placebo-controlled, parallel-group, multicentre study to determine the efficacy and safety of 2 doses of retigabine immediate release (900 mg/day and 600 mg/day) used as adjunctive therapy in adult Asian subjects with drug-resistant partial-onset seizures. Recruiting 114873 phase 3 A Multicentre, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults with Partial Onset Seizures (Extension of Study RTG114855) Not yet recruiting 115049 n\a Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy Completed 115476 phase 3 Meta-Analysis of VRX-RET-E22-303 and VRX-RET-E22-304: Two Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Studies of Retigabine in Adult Epilepsy Patients with Partial-onset Seizures (Extensions of Studies VRX-RET-E22-301 and VRX-RET-E22-302) Completed 115587 phase 4 Retigabine Observational Study in Epilepsy (ROSE) Study Not yet recruiting 115860 phase 1 An open-label, randomized, single centre, 4-way crossover study to evaluate the pharmacokinetics of single oral doses of ezogabine/retigabine in healthy adult Taiwanese subjects Completed 115981 A post marketing surveillance study to monitor the risk of urinary retention in retigabine users Active not recruiting 116158 phase 4 An open label study to evaluate the effects of ezogabine/retigabine added to existing anti-epileptic drug(s) on urinary voiding function in subjects with partial onset seizures Not yet recruiting 116216 phase 1 An interaction study to assess the effect of the ezogabine/retigabine and the main metabolite NAMR on the pharmacokinetics of digoxin in healthy volunteers Completed 116247 phase 1 An open-label, single centre, parallel group study to evaluate the safety and pharmacokinetics of single oral doses of retigabine extended release (XR) formulation in healthy adult Japanese and Caucasian subjects Terminated 116771 European Survey of Patient and Prescriber Understanding of Risks Associated with Trobalt™ Active not recruiting 116878 phase 4 Study PTG116878, a Dose-Optimization Study of Ezogabine/Retigabine Immediate Release Tablets versus Placebo in the Adjunctive Treatment of Subjects with Partial-Onset Seizures Terminated 116931 Systematic Review and Meta-Analysis: Retigabine for Adjunctive Therapy in Partial Epilepsy – updated review for Canada Recruiting VRX-RET-E22-301 phase 3 A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures Completed VRX-RET-E22-302 phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures Completed
